PATHOPHYSIOLOGY OF PEMPHIGUS IN VIVO
天疱疮体内病理生理学
基本信息
- 批准号:6534284
- 负责人:
- 金额:$ 28.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-09-15 至 2003-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Pemphigus is an organ specific autoimmune disease. Over the last two decades, the molecular basis and pathophysiology of the disease has been defined as follows. IgG class autoantibodies target molecules of the cadherin supergene family. In pemphigus foliaceus, (PF), the autoantigen is Desmoglein 1 (Dsg1). In pemphigus vulgaris (PV), autoantibodies recognize Desmoglein 3 (Dsg3)1 in patients with just oral disease, and both Dsg3 and Dsg1 in those with mucocutaneous invovlement2. The autoantibodies have been proven by us to play a primary pathogenic role in the blister formation by a passive transfer model in neonatal mice 3. The importance of Dsg3 as an adhesion molecule was confirmed when genetically engineered mice with a targeted disruption of Dsg3 gene developed mucocutaneous lesions typical of pemphigus vulgaris4. The strong linkage of disease susceptibility to HLA DR4 and DR6 genes has also been established5,6,7. However, current models do not allow us to examine the initiation of autoimmunity against these antigens, the natural course of the disease or potential immunologic interventions. The goal of our study is to develop an active autoimmune model of PV by breaking immune tolerance in susceptible strains of mice using three different strategies: 1. To break immune tolerance in transgenic mice expressing the human HLA DR4 gene (HLA-DRB1*0402) by immunization with recombinant human Dsg3. 2. To break immune tolerance in mice by injection with naive antigen presenting cells (APC), derived from murine fetuses of the same genetic background, and pulsed with recombinant human Dsg3. 3. To break immune tolerance in mice by immunizing with murine fibroblasts, stably transfected with full length of murine major histocompatibility complex (MHC) class II molecule and the extracellular portion of murine Dsg3. Pemphigus is a "clean" model of autoimmunity, and is an ideal candidate disease that could allow us to study fundamental mechanisms of autoimmunity, potential immune manipulation and immunologic therapies. This cannot occur in the absence of an active disease model, which we propose to develop by these studies.
天疱疮是一种器官特异性自身免疫性疾病。 在过去的二十年中,该疾病的分子基础和病理生理学定义如下。 IgG类自身抗体靶向钙粘蛋白超基因家族的分子。 在落叶型天疱疮(PF)中,自身抗原是桥粒芯糖蛋白1(Dsg 1)。 在寻常型天疱疮(PV)中,自身抗体在仅患有口腔疾病的患者中识别桥粒芯糖蛋白3(Dsg 3)1,在皮肤粘膜受累的患者中识别Dsg 3和Dsg 1 2。 我们已经通过新生小鼠被动转移模型证明了自身抗体在水疱形成中起主要致病作用3。 Dsg 3作为一种粘附分子的重要性得到了证实,当基因工程小鼠与Dsg 3基因的靶向破坏发展典型的寻常天疱疮粘膜皮肤病变4。 疾病易感性与HLADR 4和DR 6基因的强连锁也已建立5,6,7。然而,目前的模型不允许我们检查针对这些抗原的自身免疫的起始、疾病的自然病程或潜在的免疫干预。 本研究的目的是通过使用三种不同的策略打破敏感品系小鼠的免疫耐受来建立PV的主动自身免疫模型:1。 目的通过重组人Dsg 3免疫表达人HLA-DRB 1 *0402基因的转基因小鼠,打破免疫耐受。 2. 通过注射来自相同遗传背景的鼠胎儿的幼稚抗原呈递细胞(APC)并用重组人Dsg 3脉冲来破坏小鼠中的免疫耐受。 3. 通过用鼠成纤维细胞免疫来破坏小鼠中的免疫耐受,所述鼠成纤维细胞用全长鼠主要组织相容性复合物(MHC)II类分子和鼠Dsg 3的细胞外部分稳定转染。天疱疮是一种“干净”的自身免疫模型,是一种理想的候选疾病,可以让我们研究自身免疫的基本机制,潜在的免疫操纵和免疫治疗。 这在没有活动性疾病模型的情况下是不可能发生的,我们建议通过这些研究开发这种疾病模型。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil.
- DOI:10.1001/archderm.139.6.739
- 发表时间:2003-06
- 期刊:
- 影响因子:0
- 作者:D. Mimouni;G. Anhalt;Deborah L. Cummins;D. Kouba;Jennifer E. Thorne;H. Nousari
- 通讯作者:D. Mimouni;G. Anhalt;Deborah L. Cummins;D. Kouba;Jennifer E. Thorne;H. Nousari
Paraneoplastic pemphigus
- DOI:10.1111/j.1087-0024.2004.00832.x
- 发表时间:2004-01-01
- 期刊:
- 影响因子:0
- 作者:Anhalt, GJ
- 通讯作者:Anhalt, GJ
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GRANT J ANHALT其他文献
GRANT J ANHALT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GRANT J ANHALT', 18)}}的其他基金
AN OPEN-LABEL, DOSE-ESCALATION, PHASE I STUDY TO ASSESS PI-0824 SAFETY
评估 PI-0824 安全性的开放标签、剂量递增、I 期研究
- 批准号:
7200751 - 财政年份:2005
- 资助金额:
$ 28.61万 - 项目类别:
An Open-Label, Dose-Escalation, Phase I Study to Assess PI-0824 Safety
评估 PI-0824 安全性的开放标签、剂量递增、第一阶段研究
- 批准号:
7044705 - 财政年份:2003
- 资助金额:
$ 28.61万 - 项目类别:
CHARACTERIZATION OF THE PEMPHIGUS FOLIACEUS ANTIGEN
落叶型天疱疮抗原的特征
- 批准号:
3160272 - 财政年份:1991
- 资助金额:
$ 28.61万 - 项目类别:
CHARACTERIZATION OF THE PEMPHIGUS FOLIACEUS ANTIGEN
落叶型天疱疮抗原的特征
- 批准号:
3160274 - 财政年份:1991
- 资助金额:
$ 28.61万 - 项目类别:
CHARACTERIZATION OF THE PEMPHIGUS FOLIACEUS ANTIGEN
落叶型天疱疮抗原的特征
- 批准号:
3160273 - 财政年份:1991
- 资助金额:
$ 28.61万 - 项目类别:
PATHOGENICITY OF PEMPHIGUS AND PEMPHIGOID ANTIBODIES
天疱疮和类天疱疮抗体的致病性
- 批准号:
3071305 - 财政年份:1987
- 资助金额:
$ 28.61万 - 项目类别:
PATHOGENICITY OF PEMPHIGUS AND PEMPHIGOID ANTIBODIES
天疱疮和类天疱疮抗体的致病性
- 批准号:
3071307 - 财政年份:1987
- 资助金额:
$ 28.61万 - 项目类别:
PATHOGENICITY OF PEMPHIGUS AND PEMPHIGOID ANTIBODIES
天疱疮和类天疱疮抗体的致病性
- 批准号:
3071308 - 财政年份:1987
- 资助金额:
$ 28.61万 - 项目类别:
相似海外基金
Immunomodulatory effects of desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) in mucosal pemphigus vulgaris
桥粒芯糖蛋白 3 嵌合自身抗体受体 T 细胞 (DSG3-CAART) 对粘膜寻常型天疱疮的免疫调节作用
- 批准号:
10679911 - 财政年份:2023
- 资助金额:
$ 28.61万 - 项目类别:
Elucidating the immunology of autoantibody formation and function in COVID-19
阐明 COVID-19 中自身抗体形成和功能的免疫学
- 批准号:
10639707 - 财政年份:2023
- 资助金额:
$ 28.61万 - 项目类别:
Analysis of abnormal post-translational modifications that promote autoantibody production using high-precision mass spectrometry
使用高精度质谱分析促进自身抗体产生的异常翻译后修饰
- 批准号:
23K07915 - 财政年份:2023
- 资助金额:
$ 28.61万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clinical application based on the molecular mechanism of autoantibody production in autoimmunity
基于自身抗体产生的分子机制在自身免疫中的临床应用
- 批准号:
23K18361 - 财政年份:2023
- 资助金额:
$ 28.61万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Dynamic prediction of type 1 diabetes risk and autoantibody status by a joint model of longitudinal and multistate models
通过纵向和多状态模型的联合模型动态预测1型糖尿病风险和自身抗体状态
- 批准号:
10630731 - 财政年份:2023
- 资助金额:
$ 28.61万 - 项目类别:
Novel therapeutic strategies targeting autoantibody-producing RP105-negative B cells by t-SNE method
通过 t-SNE 方法针对产生自身抗体的 RP105 阴性 B 细胞的新治疗策略
- 批准号:
23K07910 - 财政年份:2023
- 资助金额:
$ 28.61万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Extracellular vesicle and autoantibody production
细胞外囊泡和自身抗体的产生
- 批准号:
23K15265 - 财政年份:2023
- 资助金额:
$ 28.61万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of mechanism of autoantibody production in pemphigus in conjunction with information from single cell analysis
结合单细胞分析信息阐明天疱疮自身抗体产生的机制
- 批准号:
22K08416 - 财政年份:2022
- 资助金额:
$ 28.61万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Influence of HTLV-1 for autoantibody production system and Th subset
HTLV-1对自身抗体产生系统和Th亚群的影响
- 批准号:
22K08552 - 财政年份:2022
- 资助金额:
$ 28.61万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Multi-Platform Homogeneous Multiplexed Autoantibody Assay Based on Liquid Micropiston-Enhanced Time-Resolved Forster Resonance Energy Transfer
基于液体微活塞增强时间分辨福斯特共振能量转移的多平台同质多重自身抗体测定
- 批准号:
10576777 - 财政年份:2022
- 资助金额:
$ 28.61万 - 项目类别: